These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 24758331)

  • 1. Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.
    Szakács G; Hall MD; Gottesman MM; Boumendjel A; Kachadourian R; Day BJ; Baubichon-Cortay H; Di Pietro A
    Chem Rev; 2014 Jun; 114(11):5753-74. PubMed ID: 24758331
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion.
    Lorendeau D; Dury L; Nasr R; Boumendjel A; Teodori E; Gutschow M; Falson P; Di Pietro A; Baubichon-Cortay H
    Curr Med Chem; 2017; 24(12):1186-1213. PubMed ID: 27855620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of multidrug resistance in the age of targeted therapy.
    Türk D; Szakács G
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salinomycin: A new paradigm in cancer therapy.
    Dewangan J; Srivastava S; Rath SK
    Tumour Biol; 2017 Mar; 39(3):1010428317695035. PubMed ID: 28349817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferrocene-embedded flavonoids targeting the Achilles heel of multidrug-resistant cancer cells through collateral sensitivity.
    Pérès B; Nasr R; Zarioh M; Lecerf-Schmidt F; Di Pietro A; Baubichon-Cortay H; Boumendjel A
    Eur J Med Chem; 2017 Apr; 130():346-353. PubMed ID: 28273561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
    Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
    PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical strategies to overcome resistance against targeted anticancer therapeutics.
    Pisa R; Kapoor TM
    Nat Chem Biol; 2020 Aug; 16(8):817-825. PubMed ID: 32694636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marine Natural Products as Models to Circumvent Multidrug Resistance.
    Long S; Sousa E; Kijjoa A; Pinto MM
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27399665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on tumor cells' multidrug resistance and its reversion by Chinese herbs].
    Chen XY; Liu JT
    Zhong Xi Yi Jie He Xue Bao; 2003 Sep; 1(3):221-5. PubMed ID: 15339569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells.
    Mirzaei SA; Gholamian Dehkordi N; Ghamghami M; Amiri AH; Dalir Abdolahinia E; Elahian F
    Toxicol Appl Pharmacol; 2017 Dec; 337():22-29. PubMed ID: 29079042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs.
    Patanè S
    Int J Cardiol; 2014 Oct; 176(3):1306-8. PubMed ID: 25131921
    [No Abstract]   [Full Text] [Related]  

  • 15. Nanotechnology approaches for personalized treatment of multidrug resistant cancers.
    Minko T; Rodriguez-Rodriguez L; Pozharov V
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1880-95. PubMed ID: 24120655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
    Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic significance of ectophosphatase inhibitors in reversal of multi-drug resistance.
    Kannan S
    Med Hypotheses; 2006; 66(5):1041-2. PubMed ID: 16446053
    [No Abstract]   [Full Text] [Related]  

  • 18. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
    Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
    Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gambogic acid-loaded pH-sensitive mixed micelles for overcoming breast cancer resistance.
    Wang S; Yang Y; Wang Y; Chen M
    Int J Pharm; 2015 Nov; 495(2):840-8. PubMed ID: 26407923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
    Xue X; Liang XJ
    Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.